tbuckley/cabot-search huggingface dataset:
Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study
Authors: V Nell-Duxneuner, K Machold, T Stamm, G Eberl, H Heinzl, E Hoefler, J S Smolen, G Steiner
Journal: Annals of the Rheumatic Diseases (2009)

Objective: To investigate time courses of autoantibody profiles in patients with early arthritis. Patients and methods: A total of 200 patients with very early arthritis (&lt;3 months duration), among them 102 patients with a final diagnosis of rheumatoid arthritis (RA) and 98 with other rheumatic diseases, were followed up for several years. First follow-up testing was performed in all patients (mean 5 months from baseline), and 82 patients with RA and 35 patients without RA were available for last follow-up testing (mean 32 months from baseline). IgM-rheumatoid factor (RF) was measured by nephelometry, IgA-RF, IgG-RF and anti-cyclic citrullinated peptide antibodies (ACPA) by ELISA, and anti-RA33 antibodies were determined by immunoblotting. Results: At baseline, IgA-RF was detectable in 29% and IgG-RF in 14% of patients with RA while IgM-RF&gt;50 IU/ml (RF50) was positive in 45% of the patients; specificities were 97%, 99% and 96%, respectively. However, the vast majority of patients positive for IgA-RF or IgG-RF were also positive for RF50 or ACPA. During follow-up, the prevalence of ACPA slightly increased while prevalence of all RF subtypes and anti-RA33 decreased. Remarkably, the number of patients positive for RF50 and/or ACPA remained constant, and these patients had a highly increased risk for developing erosive disease in contrast to patients solely positive for anti-RA33. Conclusions: Testing for RF subtypes did not provide additional diagnostic information. Patients positive for RF50 and/or ACPA had an unfavourable prognosis, irrespectively of changes in the antibody profile during follow-up, whereas anti-RA33 positivity was inversely associated with erosiveness at baseline and at later time points.
An assessment of lung volumes and gas transfer in sickle-cell anaemia
Authors: G. J. Miller, G. R. Serjeant
Journal: Thorax (1971)

Lung volumes, gas transfer, and anthropometry were assessed in sickle-cell anaemia in 13 patients with previous pulmonary episodes and 12 without this history. Respiratory symptoms were assessed with a standard questionnaire, total lung capacity and its subdivisions, the carbon monoxide transfer factor (TF), diffusion capacity of the alveolar capillary membrane (Dm), and the alveolar capillary blood volume (Vc) were measured, and stature, sitting height and chest diameters were recorded. Total lung capacity and vital capacity were reduced because the thorax was small relative to body size in these patients. TF was reduced by anaemia, small lungs, and a low Dm which was not simply a consequence of small lungs. This reduction tended to be offset by an increase in Vc. The cause of the reduction in Dm above that due to small lungs was probably located in the pulmonary circulation. Anaemia was considered unlikely to be responsible, and although a difference between the reactivity of carbon monoxide with Hb A and Hb S may have contributed to the reduction in Dm and the increase in Vc, it was thought unlikely to be the only cause: Dm was significantly lower in patients with a history of pulmonary complications and in non-smokers than in those without this history and in smokers. Alveolar capillary collapse or occlusion may also have reduced Dm in sickle-cell anaemia and accounted for the greater reductions in those with previous pulmonary episodes and in non-smokers.
Lynn Payer Rosemary Biggs Elizabeth Jane Bridger Patricia Frances de Carteret Coles (nee Falle) Margaret Balfour Dempster Pamela Jill Marsden (nee Coope) Valerie Joyce Metcalf (nee Richardson) Roza Merzer Marie-Luise Barbara Seidler
Authors: L. Newman, C. Rizza, C J Cutting, G M Bryce, C J Mann, E. d. C Spalding, C J S Duff, H. Marsden, J. Metcalf, A M Merzer, R. Watts
Journal: BMJ (2001)
The prevalence and characteristics of pruritus in patients with heart failure
Authors: O. Niklasson, K. Boman, B. Stenberg
Journal: British Journal of Dermatology (2015)

Pruritus (itching) can be a distressing symptom, and previous research suggests that it is common in patients with chronic heart failure (CHF).The primary aim was to examine the prevalence of itching in patients with CHF and to compare this first to that among patients with coronary artery disease (CAD) and second to that of a normal Swedish population. The study also explored characteristics and possible causes of pruritus in patients with CHF.In this cross-sectional prevalence study, a questionnaire was sent to 130 patients with CHF and to 130 with CAD. A total of 85 patients with CHF (65·4%) and 82 with CAD (63·1%) participated. Data were also compared with those of a previous study examining symptoms in a normal Swedish population.The prevalence of itching at some point during the last 3 months was 40·0% in patients with CHF and 23·2% in patients with CAD (P = 0·019). This difference was not significant after adjusting for sex, age and medication. Patients with CHF described their pruritus as more disturbing than patients with CAD. In addition, 13·6% of patients with CHF and 3·8% of persons in the normal population experienced itching every week without any rash (P = 0·001).Pruritus is common and sometimes disturbing in patients with CHF and warrants clinical attention. Medication should be considered as a cause of itching and may explain differences in the prevalence between patients with CHF and those with CAD. However, other causes of itching in patients with CHF should be explored in prospective studies.
Involvement of Hormonal and Neuromodulatory Systems in the Regulation of Memory Storage
Authors: J L McGaugh
Journal: Annual Review of Neuroscience (1989)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial
Authors: Bertrand Godeau, Sylvie Chevret, Bruno Varet, François Lefrère, Jean-Marc Zini, François Bassompierre, Stéphane Chèze, Eric Legouffe, Cyrille Hulin, Marie-José Grange, Olivier Fain, Philippe Bierling
Journal: The Lancet (2002)
Prediction of celiac disease at endoscopy
Authors: Kassem Barada, Robert Habib, Ahmad Malli, Jana Hashash, Houssam Halawi, Karim Maasri, Ayman Tawil, Fadi Mourad, Ala Sharara, Assaad Soweid, Ismail Sukkarieh, Zaher Chakhachiro, Mark Jabbour, Alessio Fasano, Debbie Santora, Carolina Arguelles, Joseph Murray, Peter Green
Journal: Endoscopy (2014)

<b>Background and study aims: </b>Celiac disease is increasingly recognized worldwide, but guidelines on how to detect the condition and diagnose patients are unclear. In this study the prevalence and predictors of celiac disease were prospectively determined in a cross-sectional sample of Lebanese patients undergoing esophagogastroduodenoscopy (EGD). <b>Patients and methods: </b>Consecutive consenting patients (n = 999) undergoing EGD answered a questionnaire and had blood taken for serologic testing. Endoscopic markers for celiac disease were documented and duodenal biopsies were obtained. The diagnosis of celiac disease was based on abnormal duodenal histology and positive serology. Risk factors were used to classify patients to either high or low risk for celiac disease. Independent predictors of celiac disease were derived via multivariate logistic regression. <b>Results: </b>Villous atrophy (Marsh 3) and celiac disease were present in 1.8 % and 1.5 % of patients, respectively. Most were missed on clinical and endoscopic grounds. The sensitivity of tissue transglutaminase (tTG) testing for the diagnosis of villous atrophy and celiac disease was 72.2 % and 86.7 %, respectively. The positive predictive value of the deamidated gliadin peptide (DGP) test was 34.2 % and that of a strongly positive tTG was 80 %. While the strongest predictor of celiac disease was a positive tTG (odds ratio [OR] 131.7, 95 % confidence interval [CI] 29.0 – 598.6), endoscopic features of villous atrophy (OR 64.8, 95 %CI 10.7 – 391.3), history of eczema (OR 4.6, 95 %CI 0.8 – 28.8), anemia (OR 6.7, 95 %CI 1.2 – 38.4), and being Shiite (OR 5.4, 95 %CI 1.1 – 26.6) significantly predicted celiac disease. A strategy of biopsying the duodenum based on independent predictors had a sensitivity of 93 % – 100 % for the diagnosis of celiac disease, with an acceptable (22 % – 26 %) rate of performing unnecessary biopsies. A strategy that excluded pre-EGD serology produced a sensitivity of 93 % – 94 % and an unnecessary biopsy rate of 52 %. <b>Conclusion:</b> An approach based solely on standard clinical suspicion and endoscopic findings is associated with a significant miss rate for celiac disease. A strategy to biopsy based on the derived celiac disease prediction models using easily obtained information prior to or during endoscopy, maximized the diagnosis while minimizing unnecessary biopsies.
PRICK‐ AND RADIOALLERGSORBENT TESTS (RAST) TO ALCALASE® IN A POPULATION NOT EXPOSED TO ENZYME DETERGENTS
Authors: B. SIMESEN, L. WIDE, H. ZACHARIAE
Journal: Allergy (1976)

A total of 301 persons in a population unexposed to enzyme detergents (Rumania) were prick-tested with Alcalase, and RASTs were performed on their sera. The material consisted of three groups, one atopic, the second non atopic, and the third healthy. In the first two groups the percentage of positive prick-test reactions amounted to 6 and 5% respectively. Only one positive RAST was found (second group). In the third group no positive prick-tests were found and no positive RASTs. The majority of the positive prick-tests were considered non specific, and no correlation was found between results of prick-tests and RASTs in this material of non exposed individuals.
YAP/TEAD–Mediated Transcription Controls Cellular Senescence
Authors: Qi Xie, Jing Chen, Han Feng, Shengyi Peng, Ursula Adams, Yujie Bai, Li Huang, Ji Li, Junjian Huang, Songshu Meng, Zengqiang Yuan
Journal: Cancer Research (2013)

Transcription coactivator Yes-associated protein (YAP) plays an important role in the regulation of cell proliferation and apoptosis. Here, we identify a new role of YAP in the regulation of cellular senescence. We find that the expression levels of YAP proteins decrease following the replication-induced cellular senescence in IMR90 cells. Silencing of YAP inhibits cell proliferation and induces premature senescence. In additional experiments, we observe that cellular senescence induced by YAP deficiency is TEAD- and Rb/p16/p53-dependent. Furthermore, we show that Cdk6 is a direct downstream target gene of YAP in the regulation of cellular senescence, and the expression of Cdk6 is through the YAP-TEAD complex. Ectopic expression of Cdk6 rescued YAP knockdown-induced senescence. Finally, we find that downregulation of YAP in tumor cells increases senescence in response to chemotherapeutic agents, and YAP or Cdk6 expression rescues cellular senescence. Taken together, our findings define the critical role of YAP in the regulation of cellular senescence and provide a novel insight into a potential chemotherapeutic avenue for tumor suppression.
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
Authors: Steven P. Treon, Christina K. Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy, Stacey Chuma, Lian Xu, Yang Cao, Guang Yang, Xia Liu, Christopher J. Patterson, Diane Warren, Zachary R. Hunter, Barry Turnbull, Irene M. Ghobrial, Jorge J. Castillo
Journal: Blood (2014)
Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience
Authors: James A Suero, Steven P Marso, Philip G Jones, Steven B Laster, Kenneth C Huber, Lee V Giorgi, Warren L Johnson, Barry D Rutherford
Journal: Journal of the American College of Cardiology (2001)
Incidence of primary systemic vasculitides in Vilnius: a university hospital population based study
Authors: J Dadoniene
Journal: Annals of the Rheumatic Diseases (2005)

Our observation of conspicuous LC suggests that lymphangiogenesis may occur in JIA synovitis.In chronic synovitis, neogenesis of LC seems to be aimed at improving drainage and thus promoting homoeostasis in the JS.
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
Authors: P. P. Tak, W. F. Rigby, A. Rubbert-Roth, C. G. Peterfy, R. F. van Vollenhoven, W. Stohl, E. Hessey, A. Chen, H. Tyrrell, T. M. Shaw
Journal: Annals of the Rheumatic Diseases (2010)

<h3>Objectives</h3> Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX. <h3>Methods</h3> In this double-blind randomised controlled phase III study, 755 MTX-naïve patients with active RA were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX. The primary end point at week 52 was the change in joint damage measured using a Genant-modified Sharp score. <h3>Results</h3> 249, 249 and 250 patients were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX, respectively. At week 52, treatment with rituximab 2×1000 mg + MTX compared with MTX alone was associated with a reduction in progression of joint damage (mean change in total modified Sharp score 0.359 vs 1.079; p=0.0004) and an improvement in clinical outcomes (ACR50 65% vs 42%; p&lt;0.0001); rituximab 2×500 mg + MTX improved clinical outcomes (ACR50 59% vs 42%; p&lt;0.0001) compared with MTX alone but did not significantly reduce the progression of joint damage. Safety outcomes were similar between treatment groups. <h3>Conclusions</h3> Treatment with rituximab 2×1000 mg in combination with MTX is an effective therapy for the treatment of patients with MTX-naïve RA. CLinicalTrials.gov identifier NCT00299104.
Novel hydroxyapatite/chitosan bilayered scaffold for osteochondral tissue-engineering applications: Scaffold design and its performance when seeded with goat bone marrow stromal cells
Authors: Joaquim M. Oliveira, Márcia T. Rodrigues, Simone S. Silva, Patrícia B. Malafaya, Manuela E. Gomes, Carlos A. Viegas, Isabel R. Dias, Jorge T. Azevedo, João F. Mano, Rui L. Reis
Journal: Biomaterials (2006)
Treatment of Nonmetastatic Cranial Parameningeal Rhabdomyosarcoma in Children Younger Than 3 Years Old: Results From International Society of Pediatric Oncology Studies MMT 89 and 95
Authors: Anne-Sophie Defachelles, Annie Rey, Odile Oberlin, David Spooner, Michael C.G. Stevens
Journal: Journal of Clinical Oncology (2009)

Purpose To explore a strategy by which radiotherapy (RT) could be avoided in the treatment of young children with parameningeal rhabdomyosarcoma (PM RMS). Patients and Methods Fifty-nine children (median age, 2 years 3 months) with nonmetastatic cranial PM RMS were treated in the International Society of Pediatric Oncology MMT 89 and 95 trials between 1989 and 2003. Results Five-year EFS and OS rates were 46% and 54%, respectively, for the whole group. No standard clinical or pathologic variables had prognostic impact. Fifty (85%) of 59 patients achieved complete local control either with (n = 28) or without (n = 22) RT administered as part of their primary treatment. Nine patients (15%) did not achieve local control (four of whom had had RT), and all died. Patients who received RT had a significantly superior 5-year EFS rate compared with patients who did not receive RT (59% v 28%, respectively). Twenty-three patients (48%) experienced relapse at a median interval of 15 months. Ultimately, only seven patients (12%) were cured without RT, although this represented 32% of those who achieved local control with initial chemotherapy. Conclusion Despite concerns about the late effects of its use in young children, cure of PM RMS remains unlikely without systematic use of RT. The accurate prediction of the small subset of patients who achieve local control without RT and who do not experience relapse would provide an opportunity for a minority of patients to avoid RT.
Variability in airway inflammation sampled by bronchoalveolar lavage
Authors: RE Ruffin
Journal: European Respiratory Journal (1996)

The study by WARD et al. [1], designed to examine the variability in airway inflammation sampled by bronchoalveolar lavage in stable asthmatics, is a worthwhile and commendable piece of research.However, given the variability in the methacholine responsiveness found on the two separate study days, there are some issues with regard to the data analysis.Previous workers have suggested that greater than a plus or minus twofold change in airway responsiveness could be regarded as significant [2].If one accepts that, in the study by WARD et al. [1], a greater than fourfold difference in the provocative dose of methacholine causing a 20% decrease in forced expiratory volume in one second (PD20) between the two study days can be considered as significantly different, then five patients should have been excluded from their analysis, i.e. patients No. 6, 12, 13, 15 and 20.These subjects had a variation in their PD20 of 5.3 to 125 fold between the two study days.If this subgroup were removed, and they could have been removed prospectively if the criteria for similar asthmatic status had included PD20 variation, what effect is there on the conclusions of the study?Determinants of asthma stability relate to symptoms, medications, airway function, and also airway responsiveness.Limits for the comparison could be set for each of these items.The study [1] illustrates the challenge that we have in accepting absolute numbers that have been measured, without considering the errors that can occur.The team from Melbourne should be congratulated on their efforts to provide more evidence for the variability of measurements.
Origin and Evolution of Water Oxidation before the Last Common Ancestor of the Cyanobacteria
Authors: Tanai Cardona, James W. Murray, A. William Rutherford
Journal: Molecular Biology and Evolution (2015)

Photosystem II, the water oxidizing enzyme, altered the course of evolution by filling the atmosphere with oxygen. Here, we reconstruct the origin and evolution of water oxidation at an unprecedented level of detail by studying the phylogeny of all D1 subunits, the main protein coordinating the water oxidizing cluster (Mn4CaO5) of Photosystem II. We show that D1 exists in several forms making well-defined clades, some of which could have evolved before the origin of water oxidation and presenting many atypical characteristics. The most ancient form is found in the genome of Gloeobacter kilaueensis JS-1 and this has a C-terminus with a higher sequence identity to D2 than to any other D1. Two other groups of early evolving D1 correspond to those expressed under prolonged far-red illumination and in darkness. These atypical D1 forms are characterized by a dramatically different Mn4CaO5 binding site and a Photosystem II containing such a site may assemble an unconventional metal cluster. The first D1 forms with a full set of ligands to the Mn4CaO5 cluster are grouped with D1 proteins expressed only under low oxygen concentrations and the latest evolving form is the dominant type of D1 found in all cyanobacteria and plastids. In addition, we show that the plastid ancestor had a D1 more similar to those in early branching Synechococcus. We suggest each one of these forms of D1 originated from transitional forms at different stages toward the innovation and optimization of water oxidation before the last common ancestor of all known cyanobacteria.
Induction of Heat Shock Response Protects the Heart Against Atrial Fibrillation
Authors: Bianca J. J. M. Brundel, Akiko Shiroshita-Takeshita, XiaoYan Qi, Yung-Hsin Yeh, Denis Chartier, Isabelle C. van Gelder, Robert H. Henning, Harm H. Kampinga, Stanley Nattel
Journal: Circulation Research (2006)

There is evidence suggesting that heat shock proteins (HSPs) may protect against clinical atrial fibrillation (AF). We evaluated the effect of HSP induction in an in vitro atrial cell line (HL-1) model of tachycardia remodeling and in tachypaced isolated canine atrial cardiomyocytes. We also evaluated the effect of HSP induction on in vivo AF promotion by atrial tachycardia-induced remodeling in dogs. Tachypacing (3 Hz) significantly and progressively reduced Ca 2+ transients and cell shortening of HL-1 myocytes over 4 hours. These reductions were prevented by HSP-inducing pretreatments: mild heat shock, geranylgeranylacetone (GGA), and transfection with human HSP27 or the phosphorylation-mimicking HSP27-DDD. However, treatment with HSP70 or the phosphorylation-deficient mutant HSP27-AAA failed to alter tachycardia-induced Ca 2+ transient and cell-shortening reductions, and downregulation (short interfering RNA) of HSP27 prevented GGA-mediated protection. Tachypacing (3 Hz) for 24 hours in vitro significantly reduced L-type Ca 2+ current and action potential duration in canine atrial cardiomyocytes; these effects were prevented when tachypacing was performed in cells exposed to GGA. In vivo treatment with GGA increased HSP expression and suppressed refractoriness abbreviation and AF promotion in dogs subjected to 1-week atrial tachycardia-induced remodeling. In conclusion, our findings indicate that (1) HSP induction protects against atrial tachycardia-induced remodeling, (2) the protective effect in HL-1 myocytes requires HSP27 induction and phosphorylation, and (3) the orally administered HSP inducer GGA protects against AF in a clinically relevant animal model. These findings advance our understanding of the biochemical determinants of AF and suggest the possibility that HSP induction may be an interesting novel approach to preventing clinical AF.